| Literature DB >> 33910935 |
Julie A Schneider1, Yutao Gong1, Kirsten B Goldberg1, Paul G Kluetz1,2, Marc R Theoret1,2, Laleh Amiri-Kordestani2, Julia A Beaver1,2, Lola Fashoyin-Aje1,2, Nicole J Gormley2, Adnan A Jaigirdar1,3, Steven J Lemery1,2, Pallavi S Mishra-Kalyani4, Gregory H Reaman1, Donna R Rivera1, Wendy S Rubinstein1,5, Harpreet Singh1,2, Rajeshwari Sridhara1, Richard Pazdur1,2.
Abstract
The FDA Oncology Center of Excellence (OCE) is a leader within the agency in scientific outreach activities and regulatory science research. On the basis of analysis of scientific workshops, internal meetings, and publications, the OCE identified nine scientific priority areas and one cross-cutting area of high interest for collaboration with external researchers. This article describes the process for identifying these scientific interest areas and highlights funded and unfunded opportunities for external researchers to work with FDA staff on critical regulatory science challenges. ©2021 American Association for Cancer Research.Entities:
Mesh：
Year: 2021 PMID： 33910935 PMCID： PMC8551300 DOI： 10.1158/1078-0432.CCR-20-4429
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531